XML 59 R44.htm IDEA: XBRL DOCUMENT v3.24.1

Earnings per share (Tables)

6 Months Ended

Dec. 31, 2023

Text block [abstract]

Summary of earnings per share

		Consolidated December 2023 $				Consolidated December 2022 $
Loss after income tax attributable to the owners of Kazia Therapeutics Limited			(8,823,513	)			(13,586,027	)
		Number				Number
Weighted average number of ordinary shares used in calculating basic earnings per share			239,779,384				145,661,097
Weighted average number of ordinary shares used in calculating diluted earnings per share			239,779,384				145,661,097
		Cents				Cents
Basic earnings per share			(3.680	)			(9.327	)
Diluted earnings per share			(3.680	)			(9.327	)

X

- Definition

The disclosure of earnings per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 33
-IssueDate 2023-01-01
-Paragraph 66
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard
-URIDate 2023-03-23

+ Details

Name:	ifrs-full_EarningsPerShareExplanatory
Namespace Prefix:	ifrs-full_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Text block [abstract]

+ References

No definition available.

+ Details

Name:	kzia_TextBlockAbstract
Namespace Prefix:	kzia_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration